Catalogo dei prodotti della ricerca

GALLO, GIOVANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.936
EU - Europa 801
AS - Asia 440
AF - Africa 30
SA - Sud America 16
OC - Oceania 10
Totale 3.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.916
IT - Italia 331
SG - Singapore 188
SE - Svezia 127
IN - India 120
DE - Germania 94
CN - Cina 51
IE - Irlanda 47
ID - Indonesia 43
RO - Romania 24
GB - Regno Unito 22
RU - Federazione Russa 22
FI - Finlandia 21
UA - Ucraina 19
FR - Francia 18
BG - Bulgaria 17
TG - Togo 17
CA - Canada 15
NL - Olanda 15
BE - Belgio 14
BR - Brasile 12
AU - Australia 9
IR - Iran 6
VN - Vietnam 6
CH - Svizzera 5
IQ - Iraq 5
KR - Corea 5
PK - Pakistan 5
PL - Polonia 5
RS - Serbia 5
ZA - Sudafrica 5
AR - Argentina 4
ES - Italia 4
EG - Egitto 3
GR - Grecia 3
MX - Messico 3
PT - Portogallo 3
JM - Giamaica 2
KZ - Kazakistan 2
NO - Norvegia 2
TN - Tunisia 2
TZ - Tanzania 2
YE - Yemen 2
BD - Bangladesh 1
DK - Danimarca 1
HK - Hong Kong 1
IL - Israele 1
JP - Giappone 1
LU - Lussemburgo 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 3.233
Salva come PNG Salva come JPEG
Città #
Fairfield 313
Ashburn 152
Singapore 132
Woodbridge 130
Seattle 129
Chandler 119
Wilmington 105
Houston 103
Cambridge 84
Rome 79
Princeton 72
San Paolo di Civitate 56
Dublin 42
Jakarta 42
Lawrence 42
San Diego 41
Millbury 40
Dearborn 30
Santa Clara 27
Ann Arbor 25
Boston 25
Plano 25
Beijing 23
New York 20
Lomé 17
Sofia 17
Andover 15
Helsinki 15
Milan 15
Ozzano dell'Emilia 14
Boardman 13
Liège 12
Brescia 10
Norwalk 9
Fremont 8
Grottaferrata 8
Toronto 8
Melbourne 7
Bremen 6
Cagliari 6
Los Angeles 6
Nanjing 6
Ottawa 6
San Mateo 5
Tehran 5
Washington 5
Amsterdam 4
Bühl 4
Fasano 4
Federal 4
Grezzana 4
Ho Chi Minh City 4
Jacksonville 4
Jaú 4
Moscow 4
Mumbai 4
Pune 4
Southend 4
Vasto 4
Campo Grande 3
Des Moines 3
Domont 3
Guangzhou 3
Hyderabad 3
Islamabad 3
Jinan 3
Lappeenranta 3
Leeds 3
Menlo Park 3
Nuremberg 3
Phoenix 3
Poggibonsi 3
Portland 3
Sacramento 3
Tirano 3
Vicenza 3
Acerra 2
Alba 2
Albano Laziale 2
Anderson 2
Aubusson 2
Barcelona 2
Bari 2
Berlin 2
Bhopal 2
Bien Hoa 2
Bizerte 2
Brussels 2
Buccinasco 2
Bussolengo 2
Cairo 2
Chennai 2
Clermont 2
Dallas 2
Dodoma 2
Dundee 2
Fairfax 2
Falls Church 2
Freiburg im Breisgau 2
Gostyn 2
Totale 2.220
Salva come PNG Salva come JPEG
Nome #
Recurrence of acute coronary syndrome during inadeguate control of cardiovascular risk factors 117
Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH) 103
Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes 96
Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease 89
Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease 88
Aspirin and the Primary Prevention of Cardiovascular Diseases. An Approach Based on Individualized, Integrated Estimation of Risk 86
Cardiovascular death risk in recovered mid-range ejection fraction heart failure. insights from cardiopulmonary exercise test 83
Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction 81
β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality 80
Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists 76
null 70
The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome 68
Is early and fast blood pressure control important in hypertension management? 67
Legacy effect in the treatment of hypertension: persistent cardiovascular protection after conclusion of randomized clinical trials in hypertension 65
Blockade of the neurohormonal systems in heart failure with preserved ejection fraction. A contemporary meta-analysis 65
ARB-based combination therapy for the clinical management of hypertension and hypertension-related comorbidities: a spotlight on their use in COVID-19 patients 65
Use of fixed-dose combinations in hypertension and cardiovascular disease prevention 64
To whom recommend intensive treatment for hypertension? 61
null 60
Implications of guidelines for hypertension management in europe. 58
Risk stratification in hypertrophic cardiomyopathy. Insights from genetic analysis and cardiopulmonary exercise testing 56
Markers of cardiotoxicity in early breast cancer patients treated with a hypofractionated schedule. A prospective study 56
The “hidden side of the moon” in hypertension. When and why is dangerous low diastolic blood pressure? 53
Highlights of ESC/ESH 2018 guidelines on the management of hypertension. what every doctor Should Know 53
Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy 52
Molecular and clinical implications of natriuretic peptides in aortic valve stenosis 51
Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure 48
Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation 48
The natriuretic peptides for hypertension treatment 48
Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension. room for monotherapy? 47
Investigation of the molecular mechanisms underlying left ventricular hypertrophy in the presence of Complex I deficiency-dependent mitochondrial dysfunction 46
Role of oxidative stress in the process of vascular remodeling following coronary revascularization. 45
Comparison between european systematic coronary risk evaluation and italian cuore algorithms in adult outpatients followed by general practitioners and specialised centres 43
Sacubitril/Valsartan. Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19 43
A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era 43
Aspirin in primary prevention. 'nothing else matters' … like hypertension 42
Atrial fibrillation and ischaemic heart disease. should we use acetylsalicylic acid beside anticoagulants? 41
Natriuretic Peptides, Cognitive Impairment and Dementia. An Intriguing Pathogenic Link with Implications in Hypertension 40
Risk stratification in heart failure with mild reduced ejection fraction. European Journal of Preventive Cardiology 39
Sacubitril/valsartan for the management of heart failure. A perspective viewpoint on current evidence 38
Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension. one shot for a double strike? 38
New insight in cardiorenal syndrome. from biomarkers to therapy 37
Cardiovascular risk and the COVID-19 pandemic: a retrospective observational study in a population of healthcare professionals 36
Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company 36
A plea for smoking-free policies in COVID-19 times: cardiovascular prevention as an ally in coronavirus containment 33
[Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy] 33
Systolic blood pressure target less than 120 mmHg. the 'Chariot Allegory' in hypertension? 32
Insights from cardiopulmonary exercise testing in pediatric patients with hypertrophic cardiomyopathy 32
Targeting cyclic guanylate monophosphate in resistant hypertension and heart failure. Are sacubitril/valsartan and vericiguat synergistic and effective in both conditions? 31
Endothelial Dysfunction in Hypertension. Current Concepts and Clinical Implications 30
Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy 30
Atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac amyloidosis: from clinical management to catheter ablation indication 29
Novel ANP (Atrial Natriuretic Peptide) based therapy for hypertension: the promising role of a disease mechanism targeted approach 29
Sacubitril/Valsartan as a therapeutic tool across the range of Heart Failure phenotypes and ejection fraction spectrum 28
COVID-19 and the Forgotten Majority 27
Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan 27
Influence of exertional oscillatory breathing and its temporal behavior in patients with heart failure and reduced ejection fraction 25
null 25
Effects of two-month treatment with a mixture of natural activators of autophagy on oxidative stress and arterial stiffness in patients with essential hypertension. A pilot study 25
New approach to blood pressure control. Triple combination pill 24
Hypertension and COVID-19. Current Evidence and Perspectives 22
Impact of a NDUFC2 Variant on the Occurrence of Acute Coronary Syndromes 21
Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations 20
Features and follow-up of patients affected by noninflammatory myocarditis after coronavirus disease 2019 vaccination 19
Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set 19
null 17
Relationship Between Cardiorespiratory Fitness, Baseline Blood Pressure and Hypertensive Response to Exercise in the Ferrari Corporate Population 17
Myocardial Infarction in Patients Without Cardiovascular Risk Factors. Advanced Prediction Models to Unlock the Clinical Dilemma? 17
null 16
A mobile app-based approach in cardiovascular disease prevention: a prospective randomized study 16
New Insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications 15
Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases 15
Natriuretic Peptides. It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms 15
2017 Position paper of the italian society for cardiovascular prevention (SIPREC) for an updated clinical management of hypercholesterolemia and cardiovascular risk: executive document 15
null 15
null 14
Gender differences in acute coronary syndromes: Do they count? 13
Potential impact of statin use on day-time and night-time blood pressure levels: a retrospective analysis of a large database of 24-hour ambulatory blood pressure monitoring 13
null 13
Comparison among different electrocardiographic criteria for left ventricular hypertrophy: retrospective analysis of a large cohort of adult outpatients with hypertension 12
Endocrine functions of the heart: from bench to bedside 11
Mitochondrial dysfunction in heart failure: from pathophysiological mechanisms to therapeutic opportunities 11
Hypertension and heart failure: from pathophysiology to treatment 11
Updated Recommendations on Cardiovascular Prevention in 2022. An Executive Document of the Italian Society of Cardiovascular Prevention 11
Polymorphic variants at NDUFC2, encoding a mitochondrial complex I subunit, associate with cardiac hypertrophy in human hypertension 11
Obesity and overweight: the “elephant in the room” that we can no longer ignore. Time to SELECT treatments 10
What about chronotropic incompetence in heart failure with mildly reduced ejection fraction? Clinical and prognostic implications from the metabolic exercise combined with cardiac and kidney indexes score dataset 10
Dyslipidaemia In Hypertension 10
An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention 10
Correction to .updated recommendations on cardiovascular prevention in 2022: an executive document of the italian society of cardiovascular prevention 9
A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment 8
BNP/NT-proBNP levels are sensitive markers of impaired prognosis in patients without heart failure 8
Prevalence and clinical outcomes of white coat and masked hypertension compared to normotension and sustained hypertension. 8
Cardiopulmonary exercise testing: An increasingly important step in managing hypertrophic cardiomyopathy. 7
Potential mechanisms of the protective effects of the cardiometabolic drugs type-2 sodium-glucose transporter inhibitors and glucagon-like peptide-1 receptor agonists in heart failure 7
Update on obesity and cardiovascular risk: from pathophysiology to clinical management 7
Prevalence and clinical characteristics of true masked hypertension compared to reverse and isolated nocturnal masked hypertension 7
From cardiovascular system to brain, the potential protective role of mas receptors in COVID-19 infection 6
Position statement of the Italian Society of Cardiovascular Prevention (SIPREC) and Italian Heart Failure Association (ITAHFA) on cardiac rehabilitation and protection programs as a cornerstone of secondary prevention after myocardial infarction or revascularization 5
Obesity and cardiovascular disease: an executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC) 5
Totale 3.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.849
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020414 0 0 0 14 43 76 74 52 61 36 42 16
2020/2021469 31 16 22 8 11 104 39 54 34 39 54 57
2021/2022684 42 27 42 46 92 31 23 64 51 40 116 110
2022/2023689 142 160 50 48 62 51 22 25 32 10 45 42
2023/2024575 43 62 28 51 52 74 26 45 20 53 43 78
2024/2025392 52 119 130 91 0 0 0 0 0 0 0 0
Totale 3.581